Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Allergy Research Unit, Kingston Health Sciences Center - KGH Site, Kingston, ON, Canada.
Curr Allergy Asthma Rep. 2020 Jun 6;20(8):34. doi: 10.1007/s11882-020-00922-8.
This paper explores how the Environmental Exposure Unit (EEU) experimental model can be used to further our understanding of pharmacotherapies and immunotherapies for the treatment of allergic rhinitis (AR).
EEUs are used increasingly for the study of combination therapies, immunotherapies, and novel AR treatments. A combined antihistamine/corticosteroid nasal spray formulation was seen to have a faster onset of action relative to the therapies individually in the Environmental Exposure Chamber. House dust mite sublingual immunotherapy tablets are both safe and efficacious as evaluated by the Vienna Challenge Chamber. The Kingston EEU found that a novel peptide-based immunotherapy approach to be effective in reducing grass pollen-induced AR. Lastly, nasal filters were determined to reduce seasonal AR symptoms, given out-of-season in the Denmark Environmental Exposure Unit. EEUs are controlled, replicable models that provide valuable insight into the efficacy, onset and duration of action, and dose-related impacts of AR therapeutics, with direct clinical relevance.
本文探讨了环境暴露单元（EEU）实验模型如何用于进一步了解治疗过敏性鼻炎（AR）的药物治疗和免疫疗法。
EEU 越来越多地用于研究联合疗法、免疫疗法和新型 AR 治疗方法。在环境暴露室内，与单独使用这些疗法相比，联合抗组胺药/皮质类固醇鼻喷雾剂的起效更快。屋尘螨舌下免疫治疗片剂在维也纳挑战室评估中既安全又有效。金斯顿 EEU 发现，一种新型基于肽的免疫疗法在减少草花粉引起的 AR 方面是有效的。最后，丹麦环境暴露单元发现，在非季节使用时，鼻过滤器可减少季节性 AR 症状。EEU 是一种可控的、可复制的模型，可深入了解 AR 治疗药物的疗效、起效时间和作用持续时间以及与剂量相关的影响，具有直接的临床相关性。
